CD8A and Alzheimer disease: These findings appeared to suggest an unexpected favorable effect of P2X7R agonists in AD, but as published later, was overridden by the Aβ peptide-mediated release of chemokines, particularly CCL3, which is associated with pathogenic CD8+ T cell recruitment during AD [35].